Salvage Mastectomy Is not the Treatment of Choice for Aggressive Subtypes of Ipsilateral Breast Cancer Recurrence: A Single-Institution Retrospective Study.
Breast cancer
HER2
breast-conserving surgery
recurrence
triple-negative breast cancer
Journal
European journal of breast health
ISSN: 2587-0831
Titre abrégé: Eur J Breast Health
Pays: Turkey
ID NLM: 101709357
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
09
05
2022
accepted:
06
07
2022
entrez:
17
10
2022
pubmed:
18
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
Patients with triple-negative (TN) or human epidermal growth factor 2 (HER2)-enriched ipsilateral breast cancer recurrence (IBCR) seem to be excluded from a second breast-conserving surgery (BCS) under the assumption that salvage mastectomy would provide better oncological outcomes. The objective of this study was to describe the clinical features of these patients, to compare the two surgical alternatives (salvage mastectomy We retrospectively reviewed all the consecutive patients with histologically confirmed TN or HER2-enriched IBCR. Disease-free survival (DFS), distant disease-free survival (DDFS), overall survival (OS), and breast cancer-specific survival (BCSS) were analyzed and compared between the two groups. Eighty-five patients were affected by TN or HER2-enriched IBCR. The majority of patients (72.9%) were treated with salvage mastectomy. There was no significant difference in terms of DFS between patients receiving a second BCS or mastectomy ( Salvage mastectomy is not always necessary and it does not seem to increase survival compared to a second BCS. In patients with small aggressive subtypes of IBCR, a second conservative approach can still be evaluated and offered, presenting acceptable loco-regional control and survival.
Identifiants
pubmed: 36248756
doi: 10.4274/ejbh.galenos.2022.2022-5-3
pii: 53090
pmc: PMC9521294
doi:
Types de publication
Journal Article
Langues
eng
Pagination
315-322Informations de copyright
©Copyright 2022 by the the Turkish Federation of Breast Diseases Societies / European Journal of Breast Health published by Galenos Publishing House.
Déclaration de conflit d'intérêts
Conflict of Interest: No conflict of interest was declared by the authors.
Références
Front Oncol. 2021 Nov 23;11:734719
pubmed: 34888233
Breast Cancer Res Treat. 2011 Nov;130(2):499-505
pubmed: 21853352
Eur J Surg Oncol. 2019 Aug;45(8):1317-1327
pubmed: 30795956
J Surg Oncol. 2015 Oct;112(5):468-75
pubmed: 26374273
JAMA Oncol. 2020 Jan 01;6(1):75-82
pubmed: 31750868
Oncology. 2018;95(3):147-155
pubmed: 29847835
Plast Reconstr Surg. 2015 Apr;135(4):959-966
pubmed: 25811561
J Natl Cancer Inst. 1995 Jan 4;87(1):19-27
pubmed: 7666458
Anticancer Res. 2017 Sep;37(9):5293-5299
pubmed: 28870967
N Engl J Med. 2002 Oct 17;347(16):1227-32
pubmed: 12393819
J Plast Reconstr Aesthet Surg. 2016 Jan;69(1):14-22
pubmed: 26453182
Oncologist. 2019 Sep;24(9):e818-e827
pubmed: 30842240
Breast Cancer Res Treat. 2016 Apr;156(2):391-400
pubmed: 27008183
J Surg Res. 2021 Feb;258:23-37
pubmed: 32980773
Clin Breast Cancer. 2021 Aug;21(4):329-336
pubmed: 33431329
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Updates Surg. 2022 Apr;74(2):479-489
pubmed: 34181187
Adv Anat Pathol. 2014 Mar;21(2):100-7
pubmed: 24508693
Ann Surg Oncol. 2012 Nov;19(12):3771-6
pubmed: 22618719
Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):687-91
pubmed: 12062613
Arch Gynecol Obstet. 2016 Feb;293(2):247-69
pubmed: 26341644
Surg Oncol. 2013 Dec;22(4):247-55
pubmed: 24144808
Breast Cancer Res Treat. 2012 Jun;133(3):831-41
pubmed: 22147079
JAMA. 2019 Jan 22;321(3):288-300
pubmed: 30667505
Am J Surg. 2008 Oct;196(4):495-9
pubmed: 18809050
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
Ann Surg Oncol. 2020 Jun;27(6):1864-1874
pubmed: 31965372
Curr Breast Cancer Rep. 2016;8:112-117
pubmed: 27330677
Eur J Surg Oncol. 2013 Aug;39(8):887-91
pubmed: 23746877
N Engl J Med. 2009 Feb 19;360(8):790-800
pubmed: 19228622